7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,388 shares of the company’s stock, valued at approximately $249,000. Dynamic Technology Lab Private Ltd owned 0.05% of Inhibrx Biosciences as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in the business. Readystate Asset Management LP boosted its holdings in shares of Inhibrx Biosciences by 534.1% during the third quarter. Readystate Asset Management LP now owns 170,158 shares of the company’s stock worth $5,731,000 after purchasing an additional 143,324 shares during the last quarter. Sofinnova Investments Inc. increased its stake in Inhibrx Biosciences by 1.5% in the second quarter. Sofinnova Investments Inc. now owns 708,678 shares of the company’s stock valued at $10,113,000 after purchasing an additional 10,762 shares during the last quarter. Bridgeway Capital Management LLC acquired a new position in Inhibrx Biosciences in the second quarter valued at $235,000. Bank of America Corp DE lifted its position in Inhibrx Biosciences by 19.2% during the second quarter. Bank of America Corp DE now owns 9,130 shares of the company’s stock worth $130,000 after buying an additional 1,469 shares during the period. Finally, Mark Asset Management LP purchased a new position in Inhibrx Biosciences during the second quarter worth about $243,000. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on INBX shares. Citigroup restated a “market perform” rating on shares of Inhibrx Biosciences in a report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d)” rating on shares of Inhibrx Biosciences in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Inhibrx Biosciences has an average rating of “Reduce”.

Inhibrx Biosciences Trading Down 5.7%

Shares of INBX opened at $69.30 on Friday. Inhibrx Biosciences, Inc. has a twelve month low of $10.81 and a twelve month high of $94.57. The firm has a market capitalization of $1.01 billion, a P/E ratio of -6.92 and a beta of 1.50. The company has a current ratio of 4.49, a quick ratio of 4.49 and a debt-to-equity ratio of 2.71. The stock’s fifty day simple moving average is $76.50 and its 200 day simple moving average is $63.85.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.